Metagenics Akkermansia Review — The EU-Approved Option for UK Buyers

If you have been researching Akkermansia supplements and want the option closest to what was tested in the human clinical trials, Metagenics — sold under The Akkermansia Company brand — is the most straightforward answer. It uses pasteurised Akkermansia muciniphila ATCC BAA-835, the same strain and formulation type used in the 2019 Depommier proof-of-concept trial. It has EU Novel Food approval. And as of mid-2026, it is available on Amazon.co.uk. This review explains what you are actually buying, what the evidence says, and where the caveats lie.

Who Makes It — Metagenics and The Akkermansia Company

The product reviewed here is sold under The Akkermansia Company brand, which operates under the Metagenics group — a Belgian-headquartered nutritional supplement company with a focus on practitioner-grade, evidence-based products. Metagenics has European manufacturing infrastructure and a history of regulatory compliance in EU markets, which is directly relevant to how the Akkermansia product was developed and brought to market.

The Akkermansia Company was established specifically to commercialise the research from the Cani/Depommier laboratory at UCLouvain (Université catholique de Louvain) in Belgium — the same research group responsible for the Plovier 2017 and Depommier 2019 clinical trials that form the primary evidence base for pasteurised Akkermansia supplementation. This connection between the research origin and the commercial product is unusually direct by supplement industry standards.

The founding scientific advisor is Professor Patrice Cani — one of the world's foremost Akkermansia researchers and the scientist who identified metabolic endotoxaemia as a mechanism linking gut permeability to systemic metabolic disease. This is not a brand that licenced a bacteria name and put it in a capsule; it is the commercial arm of the laboratory that produced most of the foundational human Akkermansia research.

The Formulation

The 100 mg dose corresponds to approximately 10 billion pasteurised cells — which matches the dosing used in the Depommier 2019 human RCT, the most rigorous Akkermansia human trial to date. This direct correspondence between product dose and trial dose is a meaningful quality indicator: the clinical evidence was generated at this dose, with this strain, in this formulation type.

Why Pasteurised Matters — and Why It Works

Some buyers initially question why a heat-killed product would be effective at all. The answer lies in the Amuc_1100 protein. This outer membrane protein — identified in the Plovier 2017 study — is the primary mediator of Akkermansia's immune and metabolic benefits. It survives heat treatment at 70°C with its functional structure intact, and it continues to interact with Toll-Like Receptor 2 (TLR2) in the gut lining after pasteurisation.

In the Plovier 2017 study, purified Amuc_1100 protein alone was nearly as effective as whole live or pasteurised bacteria in improving metabolic outcomes in obese mice. The conclusion — that the protein, not bacterial viability, is the primary active component — is why the clinical evidence favours pasteurised formulations over live ones for practical supplementation purposes.

EU Novel Food Approval — What It Means

Novel Food approval from the European Food Safety Authority (EFSA) is not a minor regulatory footnote — it is a meaningful safety and quality threshold. Novel Food status is required for any food or food ingredient not previously in significant use in the EU before May 1997. Akkermansia muciniphila, being a relatively recently characterised bacterium, required this approval before it could be marketed commercially in the EU.

EFSA's 2021 Novel Food approval covers pasteurised Akkermansia muciniphila ATCC BAA-835 specifically. The approval process included:

• A comprehensive safety assessment of the bacterium and its preparations
• Review of the available toxicological and clinical data
• Assessment of potential for antibiotic resistance gene transfer
• Evaluation of the safety of the pasteurisation process
• Confirmation of the strain's identity and stability

This approval applies to the product sold by The Akkermansia Company / Metagenics. Live Akkermansia supplements — including Pendulum's product — do not have the same EFSA Novel Food approval, which is a meaningful regulatory distinction for EU and UK buyers.

What the Clinical Evidence Shows

The Metagenics/Akkermansia Company product is the direct commercial translation of the formulation used in the key human trials. The primary studies are:

It is worth noting that the Depommier 2019 trial was a proof-of-concept study with 32 participants — a small but meaningful human RCT. Larger trials are required to fully characterise the dose-response relationship and confirm findings across broader populations. The current evidence is promising and mechanistically coherent, but not yet at the scale of a Phase III pharmaceutical trial. This context matters when setting expectations.

Availability in the UK

As of mid-2026, The Akkermansia Company product is available through Amazon.co.uk — making it the most practically accessible Akkermansia supplement for UK buyers. No international shipping, no customs uncertainty, no cold chain logistics. It arrives like any other Amazon order and can be stored at room temperature.

Price positioning is at a premium — consistent with its specialist positioning and the manufacturing complexity involved in producing pharmaceutical-grade pasteurised Akkermansia. A one-month supply (30 capsules) typically costs in the region of £38–50 on Amazon.co.uk, though pricing varies and occasional discounts apply.

Strengths

• Directly linked to the research — developed by the UCLouvain laboratory responsible for the Plovier 2017 and Depommier 2019 trials; scientific credibility is as direct as it gets in the supplement space
• EU Novel Food approval — the only Akkermansia supplement with EFSA regulatory sign-off, covering exactly this strain (ATCC BAA-835) and this formulation type (pasteurised)
• Dose matches clinical trial — 10 billion pasteurised cells per capsule matches the Depommier 2019 trial dosing
• No cold chain required — room temperature storage; no degradation risk during Amazon.co.uk shipping
• Available in the UK via Amazon.co.uk — no import hassle, no customs delays, no currency conversion
• Delayed release capsule — enteric coating protects the product through stomach acid, improving delivery to the intestine where it is needed

Weaknesses

• Premium price point — at £38–50 per month, it is not a budget option; ongoing supplementation represents a significant monthly cost
• Small RCT evidence base — 32 participants in the Depommier trial is promising but not the scale of a large Phase III trial; larger studies are needed
• No direct evidence in specific conditions — the trial was in overweight insulin-resistant adults; evidence in IBS, IBD or other specific conditions is observational rather than interventional
• Availability can vary — Amazon.co.uk listings are subject to stock fluctuations; direct ordering from theakkermansia.com is an alternative but adds shipping costs

How It Compares to Pendulum

For UK buyers, the comparison is not particularly close. Metagenics/The Akkermansia Company has EU Novel Food approval (recognised by the UK FSA under the GB novel food transitional framework), direct research provenance, no cold chain challenges, local Amazon.co.uk availability, and the strongest alignment with the published clinical evidence. The only scenario in which Pendulum makes more sense for a UK buyer is if they specifically want a live formulation for theoretical colonisation reasons — and the evidence base for that preference is not currently strong.

Who Should Consider This Supplement

Based on the published evidence, the Metagenics Akkermansia supplement is most relevant for:

• People with metabolic concerns — insulin resistance, elevated fasting glucose, or metabolic syndrome — who want a gut microbiome intervention with clinical evidence
• People who have had their microbiome tested and received a low Akkermansia result
• People with IBS, IBD, or persistent gut symptoms who have already made dietary changes and want an evidence-based adjunct (noting that direct IBS/IBD trial evidence is still limited)
• People interested in supporting their immune function — particularly relevant to those managing autoimmune conditions, though direct trial evidence in these populations is preliminary
• Older adults, where age-related Akkermansia decline is most pronounced

Read Next

Brand Review

Pendulum Akkermansia Review — Is It Worth It for UK Buyers?

Read Review →

Buyer's Guide

Best Akkermansia Supplements — UK Buyer's Guide

Read Article →